Product Description
Remarkable advances have occurred since the Series 3 Fascicle published in 1995 with paradigm shifts in every dimension of our understanding of lung tumors including clinical, radiologic, histopathologic, cytopathologic, immunohistochemical, molecular and therapeutic aspects. The molecular revolution leading to effective targeted therapies and breakthroughs in immunotherapy for lung cancer have led to novel approaches incorporating the concept of personalized medicine for patients who historically had little hope. These advances have strengthened the place of pathologists to play a central role in the multidisciplinary team that is now needed to properly diagnose and manage lung cancer patients.
Customers Who Bought This Item Also Bought
*If this is not the "
Tumors of the Lower Respiratory Tract (AFIP Atlas of Tumor Pathology, Series 4)" product you were looking for, you can check the other results by
clicking this link.
Details were last updated on Nov 16, 2024 00:13 +08.